Navigation Links
NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

advantages over other pain therapies. NeurogesX' marketing authorization application to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application with the FDA in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

Neu
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Inclinix, Inc. a contract,research organization that hires ... new drugs, today announced restructuring of positions to,support ... of,40% in 2007 and the infusion of $10 ... Frontier Capital, a private equity firm., Diane ...
... SAN FRANCISCO, June 3 VIA Pharmaceuticals,(Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... chief executive officer of VIA, and,James G. Stewart, ... a company update at the Seventh Annual Needham ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc (OTC ... of plant extracts and pharmaceutical raw materials,for ... released an,update on its business following their ... "In the first quarter, sales of our ...
Cached Biology Technology:Inclinix Expansion Creates New Position and Promotions 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... to developing new antibiotics, and a technique called solid-state ... , That's the view of University of Michigan ... toward that goal March 3 at the annual meeting ... Ramamoorthy's research group is using solid-state NMR to explore ...
... Flavonoids, a group of compounds found in fruits and ... for their antioxidant activity, actually have little or no ... scientists in the Linus Pauling Institute at Oregon State ... human health, but for reasons that are quite different ...
... of the persistent riddles of the deadly 1918 Spanish ... varying severity. Why were some municipalities such as St. ... Philadelphia when both implemented similar public health measures? What ... by the National Institutes of Health (NIH), was not ...
Cached Biology News:Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3Studies force new view on biology of flavonoids 2Studies force new view on biology of flavonoids 3Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4
... workstation is the simplest, easiest-to-use system ever ... liquid handling capabilities,into their labs, or groups ... routine applications on a separate instrument. Plate-handling ... even when you have thousands of ...
... has generated hybridomas against a large ... initiation, you are provided with personalized ... cell lines developed by Covance remain ... typical hybridoma development project has four ...
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... ENGENISTM (Entire Gene/cDNA or Isolated Sequence) siRNA ... quantitative approach for evaluation of a potential ... an efficient target for RNA interference (RNAi). ... not perfect, leaving the probability of selected ...
Biology Products: